Overview

Tucidinosta Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor：a Prospective, Single-arm, Phase II Clinical Trial.

Status:
Not yet recruiting

Trial end date:
2025-04-01

Target enrollment:

Participant gender:

Summary

The study is designed to explore the clinical benefit following treatment with tucidinosta in combination with metronomic capecitabine and endocrine therapy in patients with hormone receptor-positive, Her2-negative advanced breast cancer who have received CDK4/6 Inhibitor treatment.

Phase:

Phase 2

Details

Lead Sponsor:

wang shusen

Treatments:

Anastrozole
Capecitabine
Exemestane
Fulvestrant
Letrozole